In March 2025, the Company’s Board took action to reduce the Company’s workforce by 57% resulting in a total workforce after reductions of 19 employees. The Board also decided to exit the Company’s corporate headquarters in Warminster, PA, and to discontinue in-house scientific research. In connection with these actions, the Company expects to incur a one-time restructuring charge in the first quarter of 2025 of approximately $11 million to $13 million.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABUS:
- Arbutus Biopharma reports FY24 EPS (38c), consensus (55c)
- Strategic Legal Maneuvers Bolster Buy Rating for Arbutus Biopharma Amid Global Patent Challenges
- Genevant and Arbutus File Global Patent Lawsuits Against Moderna
- Genevant, Arbutus initiate patent infringement actions against Moderna
- Biotech Alert: Searches spiking for these stocks today